Ryan Jane 4

What Happened

• Ryan Jane, a director of Neuphoria Therapeutics, was granted 8,537 restricted stock units (RSUs) on January 20, 2026. The grant is reported as an award/acquisition (code A) at $0.00 (no cash paid). The filing lists the RSUs as derivative awards that represent a contingent right to receive common shares.

Key Details

• Transaction date: 2026-01-20; Filing date (Form 4): 2026-01-21 (timely, one day after the transaction).
• Grant details: 8,537 RSUs; reported acquisition price $0.00; transaction code A (award/grant).
• Footnotes: (F1) Each RSU equals a contingent right to one share; (F2) granted under the Board’s annual remuneration policy; (F3) RSUs vest only if the reporting person remains in continuous service through the earlier of (a) the day prior to the next annual shareholder meeting (expected no later than Dec 15, 2026) or (b) a Change in Control.
• Shares owned after the transaction: not specified in the provided filing data.
• Nature of filing: award/compensation (not an open-market purchase or sale), so it is routine director compensation rather than an outright market trade.

Context

• RSUs are a form of deferred compensation that convert into shares (or their cash value) only if and when vesting conditions are met; they do not represent immediately tradable shares. Awards to directors under board remuneration policies are common and generally reflect standard compensation practices rather than direct trading sentiment.